Sarepta could be down on patient death in FDA database, says RBC Capital

Rate this post


https://www.tipranks.com/news/the-fly/sarepta-coul-dows-datientient-death–fda-database-say-rbc-capapital

RBC Capital Analyst Bryan Abraham says Sarapta’s shares (Variety) Can trade a lower FDA database today, which includes a patient’s patient’s death in November, who experienced muscle spasms and Mylagia.

Published in the first place Penurious – The final source of real-time, market moving financial news. Try now >>

See Hot Resets of Insider on Tipranks >>

Read more in Srpt:

 
Report

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *